INKT PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

INKT ▲ +11.73% at T+20d

NEUTRAL call ✓ call won +11.73% · α vs SPY +2.01% · entry $10.57 → $11.81

Next anchor: T+60d in 14d

Last close $12.02 (close Jun 12) · +13.72% from $10.57 entry

Entry anchored
Mar 31, 03:57 PM ET
via Databento tick

T+1d

+1.14%

call +1.14% · α +1.06%

$10.69

settled 2mo ago

T+5d

+8.51%

call +8.51% · α +4.75%

$11.47

settled 2mo ago

T+20d

+11.73%

call +11.73% · α +2.01%

$11.81

settled 7w ago

T+60d

—

call — · α —

—

in 14d

Price Chart

Loading chart...

Executive Summary

MiNK Therapeutics announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, in combination with N-803 for severe Coccidioides infection, has been accepted for presentation at the ATS International Conference in May 2026. No data will be disclosed ahead of the conference, and full results will be shared during the poster session. This represents early-stage clinical visibility but no new efficacy or safety results.

Actionable Insight

Traders should monitor the ATS conference presentation on May 20 for initial data on agenT-797's immune restoration potential in severe infections, which could influence near-term sentiment. Until then, no material change in valuation is supported.

Key Facts

Abstract on agenT-797 combination therapy accepted for poster presentation at ATS 2026 conference.
Presentation will occur on May 20, 2026, in Orlando, Florida; no data released in advance.
agenT-797 is in clinical development for GvHD, solid tumors, and severe pulmonary inflammation.
No financial or clinical results disclosed; next update expected at the conference.

Financial Impact

No immediate financial impact; potential for sentiment shift post-data disclosure

pipeline valueR&D progress

Risk Factors

No data available yet — clinical benefit remains unproven
High risk typical of early-stage biotech development; future results may not meet expectations

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3266508

13 reports for INKT

T+1T+5T+20T+60

50% Hit rate 3 of 6 directional calls best @ T+5▲ +5.89%Mar 31, 2026

Filters

Reports for INKT — sortable, filterable
	Type				Now
May 28, 2026 17d ago	Press Release NEUTRAL ★ 4/10	$12.20 $12.76	▲ +4.59%	▲ +4.64%	$12.02 (−1.48%)
May 20, 2026 25d ago	Press Release NEUTRAL ★ 4/10	$10.72 $10.18	▼ −5.04%	▼ −6.27%	$12.02 (+12.13%)
May 15, 2026 4w ago	8-K NEUTRAL ★ 5/10	$10.72 $10.87	▲ +1.40%	▲ +0.44%	$12.02 (+12.13%)
May 15, 2026 4w ago	Press Release BULLISH ★ 6/10	$10.72 $10.87	▲ +1.40%	▲ +0.44%	$12.02 (+12.13%)
May 14, 2026 4w ago	Press Release BULLISH ★ 7/10	$10.51 $10.94	▲ +4.09%	▲ +4.81%	$12.02 (+14.37%)
May 12, 2026 4w ago	Press Release BULLISH ★ 7/10	$11.41 $10.04	▼ −12.01%	▼ −12.08%	$12.02 (+5.35%)
May 8, 2026 5w ago	Press Release NEUTRAL ★ 2/10	$10.95 $10.04	▼ −8.31%	▼ −8.23%	$12.02 (+9.77%)
Apr 17, 2026 8w ago	Press Release BULLISH ★ 8/10	$14.21 $10.95	▼ −22.94%	▼ −23.50%	$12.02 (−15.41%)
Apr 1, 2026 10w ago	Press Release NEUTRAL ★ 3/10	$10.57 $11.47	▲ +8.51%	▲ +4.75%	$12.02 (+13.72%)
Mar 31, 2026 10w ago	8-K BULLISH ★ 7/10	$10.53 $11.15	▲ +5.89%	▲ +1.94%	$12.02 (+14.15%)

US Market Status

Market Closed — Opens in 5h 5m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access